Antitumor effect of Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, combined with cytotoxic agent on murine hepatocellular carcinoma

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 9

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

411

HTML

2118

Figures (1-1)

125

Tables (1-3)

Sum=2750

Mar 7, 2005 (publication date) through May 7, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Reports

World J Gastroenterol. Mar 7, 2005; 11(9): 1382-1386
Published online Mar 7, 2005. doi: 10.3748/wjg.v11.i9.1382

Figure 1 Inhibitory effect of Gefitinib or/and CDDP on mouse implanted H22 tumors in the first experiment “A” and in the second experiment “B”.

Citation: Zhu BD, Yuan SJ, Zhao QC, Li X, Li Y, Lu QY. Antitumor effect of Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, combined with cytotoxic agent on murine hepatocellular carcinoma. World J Gastroenterol 2005; 11(9): 1382-1386
URL: https://www.wjgnet.com/1007-9327/full/v11/i9/1382.htm
DOI: https://dx.doi.org/10.3748/wjg.v11.i9.1382